QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.120394v1 322/1/324    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burmeister, M. A. Articles by Kapusta, D. R. Search for Related Content PubMed PubMed Citation Articles by Burmeister, M. A. Articles by Kapusta, D. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Centrally Administered Nociceptin/Orphanin FQ (N/OFQ) Evokes Bradycardia, Hypotension, and Diuresis in Mice via Activation of Central N/OFQ Peptide Receptors

Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana

The present studies examined the cardiovascular and renal responses produced by activation of central nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptors in conscious mice. To assess this, we examined changes in heart rate (HR), mean arterial pressure (MAP), urine output (V), urinary sodium excretion (UNaV), and free water clearance (CH₂O) produced by acute i.c.v. injection of N/OFQ (0.03, 0.3, 1, or 3 nmol) or isotonic saline vehicle (2 µl) in conscious telemetered ICR-CD1 mice. After i.c.v. injection, N/OFQ, but not vehicle, dose dependently decreased HR and MAP and increased V. At 3 nmol, N/OFQ reduced HR [control (C), 672 ± 23 beats/min; 20 min, 411 ± 30 beats/min] and MAP (C, 108 ± 4 mm Hg; 20 min, 62 ± 6 mm Hg). In the same telemetered mice, i.c.v. N/OFQ significantly elevated V (0.65 ± 0.03 cc/2 h) compared with levels for the vehicle-treated group (0.15 ± 0.09 cc/2 h). Central N/OFQ/vehicle did not alter UNaV or CH₂O. In separate studies, 2-h i.c.v. pretreatment with the NOP receptor antagonist UFP-101 ([Nphe¹,Arg¹⁴,Lys¹⁵]N/OFQ-NH₂) (10 or 30 nmol) markedly, but transiently, reduced HR but not MAP, V, UNaV, or CH₂O. After 2-h UFP-101 (10 or 30 nmol) pretreatment, subsequent i.c.v. injection of N/OFQ (1 or 3 nmol) failed to alter cardiovascular or renal function. In contrast, in separate mice, 2-h pretreatment with N/OFQ (1 or 3 nmol) or vehicle failed to prevent the cardiodepressor and diuretic responses to a subsequent i.c.v. injection of the same dose of N/OFQ. Together, these findings demonstrate that in conscious mice, the central administration of N/OFQ evokes marked bradycardia, hypotension, and diuresis by selective activation of central NOP receptors.

Address correspondence to: Daniel R. Kapusta, Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112. E-mail: dkapus{at}lsuhsc.edu

This article has been cited by other articles:

				M. A. Burmeister, M. A. Ansonoff, J. E. Pintar, and D. R. Kapusta Nociceptin/Orphanin FQ (N/OFQ)-Evoked Bradycardia, Hypotension, and Diuresis Are Absent in N/OFQ Peptide (NOP) Receptor Knockout Mice J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 897 - 904. [Abstract] [Full Text] [PDF]